e-learning
resources
Berlin 2008
Monday, 06.10.2008
Pulmonary vascular medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term effects of bosentan in patients with human immunodeficiency virus-associated pulmonary arterial hypertension
B. Degano, J. Le Pavec, L. Savale, X. Jais, C. Tcherakian, G. Simonneau, M. Humbert, O. Sitbon (Clamart, France)
Source:
Annual Congress 2008 - Pulmonary vascular medicine
Session:
Pulmonary vascular medicine
Session type:
Oral Presentation
Number:
1583
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Degano, J. Le Pavec, L. Savale, X. Jais, C. Tcherakian, G. Simonneau, M. Humbert, O. Sitbon (Clamart, France). Long-term effects of bosentan in patients with human immunodeficiency virus-associated pulmonary arterial hypertension. Eur Respir J 2008; 32: Suppl. 52, 1583
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009
Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension
Source: Eur Respir J 2004; 23: 321-326
Year: 2004
Bosentan in pulmonary arterial hypertension associated with HIV infection
Source: Eur Respir J 2003; 22: Suppl. 45, 563s
Year: 2003
Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011
Longer-term survival in paediatric patients with idiopathic or familial pulmonary arterial hypertension treated with bosentan
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
Unique hemodynamic profile of HIV patients with portal hypertension: Comparison with HIV-associated PAH and porto-pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models
Year: 2012
Pulmonary hypertension in human immunodeficiency virus infection
Source: Eur Respir J 2002; 20: Suppl. 38, 443s
Year: 2002
Pulmonary arterial hypertension in patients with HIV infection
Source: Eur Respir Mon 2012; 57: 82-93
Year: 2012
Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 205s
Year: 2005
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment
Source: Eur Respir J 2014; 43: 1516-1519
Year: 2014
Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009
Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept